{"entity":{"type":"insider","cik":"0001821074","url":"/insider/0001821074","json_url":"/insider/0001821074.json","name":"Jacobs Bruce N.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":41,"n_filings":13,"first":"2021-03-05","last":"2026-07-02","span_basis":"filed_date"},"name_variants":[{"name":"Jacobs Bruce N.","source":"filing","n_filings":13,"first_seen":"2021-03-05","last_seen":"2026-07-02"}],"transactions":[{"id":5873448,"accession":"0001193125-26-295090","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001193125-26-295090","line_url":"/filing/0001193125-26-295090","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821074","owner_name":"Jacobs Bruce N.","owner_display_name":"Jacobs Bruce N.","owner_url":"/insider/0001821074","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":77109.0,"shares_display":"77,109","price_per_share":114.9649064985929,"price_display":"114.96","price_state":"stated","total_value":8864828.9752,"total_display":"8,864,828.98","total_whole":"8,864,829","shares_owned_after":262207.0,"shares_owned_after_display":"262,207","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-30","filed_date":"2026-07-02","scope":"insider","n_lines":8},{"id":5904842,"accession":"0001193125-26-091982","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001193125-26-091982","line_url":"/filing/0001193125-26-091982","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821074","owner_name":"Jacobs Bruce N.","owner_display_name":"Jacobs Bruce N.","owner_url":"/insider/0001821074","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4895.0,"shares_display":"4,895","price_per_share":85.29541908069459,"price_display":"85.30","price_state":"stated","total_value":417521.0764,"total_display":"417,521.08","total_whole":"417,521","shares_owned_after":234472.0,"shares_owned_after_display":"234,472","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-04","filed_date":"2026-03-04","scope":"insider","n_lines":4},{"id":5904833,"accession":"0001193125-26-091982","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-26-091982","line_url":"/filing/0001193125-26-091982","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821074","owner_name":"Jacobs Bruce N.","owner_display_name":"Jacobs Bruce N.","owner_url":"/insider/0001821074","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7576.0,"shares_display":"7,576","price_per_share":88.9268137407603,"price_display":"88.93","price_state":"stated","total_value":673709.5409,"total_display":"673,709.54","total_whole":"673,710","shares_owned_after":237483.0,"shares_owned_after_display":"237,483","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-02","filed_date":"2026-03-04","scope":"insider","n_lines":3},{"id":5069249,"accession":"0001193125-25-206350","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-206350","line_url":"/filing/0001193125-25-206350#line-2","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821074","owner_name":"Jacobs Bruce N.","owner_display_name":"Jacobs Bruce N.","owner_url":"/insider/0001821074","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":79220.0,"shares_display":"79,220","price_per_share":50.0048,"price_display":"50.00","price_state":"stated","total_value":3961380.256,"total_display":"3,961,380.26","total_whole":"3,961,380","shares_owned_after":227409.0,"shares_owned_after_display":"227,409","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-17","filed_date":"2025-09-17","scope":"insider"},{"id":5117064,"accession":"0000950170-25-031146","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-031146","line_url":"/filing/0000950170-25-031146","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821074","owner_name":"Jacobs Bruce N.","owner_display_name":"Jacobs Bruce N.","owner_url":"/insider/0001821074","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7035.0,"shares_display":"7,035","price_per_share":30.45046567164179,"price_display":"30.45","price_state":"stated","total_value":214219.026,"total_display":"214,219.03","total_whole":"214,219","shares_owned_after":203167.0,"shares_owned_after_display":"203,167","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-03","filed_date":"2025-03-03","scope":"insider","n_lines":2},{"id":2983298,"accession":"0000950170-24-025083","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-24-025083","line_url":"/filing/0000950170-24-025083","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821074","owner_name":"Jacobs Bruce N.","owner_display_name":"Jacobs Bruce N.","owner_url":"/insider/0001821074","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3934.0,"shares_display":"3,934","price_per_share":41.856684646670054,"price_display":"41.86","price_state":"stated","total_value":164664.1974,"total_display":"164,664.20","total_whole":"164,664","shares_owned_after":143907.0,"shares_owned_after_display":"143,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-04","filed_date":"2024-03-04","scope":"insider","n_lines":3},{"id":8062324,"accession":"0000899243-23-006979","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-23-006979","line_url":"/filing/0000899243-23-006979","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821074","owner_name":"Jacobs Bruce N.","owner_display_name":"Jacobs Bruce N.","owner_url":"/insider/0001821074","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1370.0,"shares_display":"1,370","price_per_share":30.996559562043796,"price_display":"31.00","price_state":"stated","total_value":42465.2866,"total_display":"42,465.29","total_whole":"42,465","shares_owned_after":104882.0,"shares_owned_after_display":"104,882","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-02","filed_date":"2023-03-03","scope":"insider","n_lines":2},{"id":6341038,"accession":"0000899243-22-002010","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-22-002010","line_url":"/filing/0000899243-22-002010","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821074","owner_name":"Jacobs Bruce N.","owner_display_name":"Jacobs Bruce N.","owner_url":"/insider/0001821074","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":51.8456028,"price_display":"51.85","price_state":"stated","total_value":777684.042,"total_display":"777,684.04","total_whole":"777,684","shares_owned_after":18936.0,"shares_owned_after_display":"18,936","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-12","filed_date":"2022-01-14","scope":"insider","n_lines":3},{"id":4268356,"accession":"0000899243-21-046845","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-21-046845","line_url":"/filing/0000899243-21-046845","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821074","owner_name":"Jacobs Bruce N.","owner_display_name":"Jacobs Bruce N.","owner_url":"/insider/0001821074","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":53.56370229,"price_display":"53.56","price_state":"stated","total_value":535637.0229,"total_display":"535,637.02","total_whole":"535,637","shares_owned_after":19801.0,"shares_owned_after_display":"19,801","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-03","filed_date":"2021-12-03","scope":"insider","n_lines":3},{"id":4509441,"accession":"0000899243-21-035158","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-035158","line_url":"/filing/0000899243-21-035158","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821074","owner_name":"Jacobs Bruce N.","owner_display_name":"Jacobs Bruce N.","owner_url":"/insider/0001821074","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":60.118005,"price_display":"60.12","price_state":"stated","total_value":601180.05,"total_display":"601,180.05","total_whole":"601,180","shares_owned_after":8756.0,"shares_owned_after_display":"8,756","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-03","filed_date":"2021-09-03","scope":"insider","n_lines":2},{"id":5392220,"accession":"0000899243-21-022025","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-022025","line_url":"/filing/0000899243-21-022025","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821074","owner_name":"Jacobs Bruce N.","owner_display_name":"Jacobs Bruce N.","owner_url":"/insider/0001821074","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":46.86950908,"price_display":"46.87","price_state":"stated","total_value":468695.0908,"total_display":"468,695.09","total_whole":"468,695","shares_owned_after":11494.0,"shares_owned_after_display":"11,494","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-03","filed_date":"2021-06-04","scope":"insider","n_lines":2},{"id":5276038,"accession":"0000899243-21-011747","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-21-011747","line_url":"/filing/0000899243-21-011747#line-4","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821074","owner_name":"Jacobs Bruce N.","owner_display_name":"Jacobs Bruce N.","owner_url":"/insider/0001821074","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8195.0,"shares_display":"8,195","price_per_share":60.1703,"price_display":"60.17","price_state":"stated","total_value":493095.6085,"total_display":"493,095.61","total_whole":"493,096","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-15","filed_date":"2021-03-15","scope":"insider"},{"id":5276031,"accession":"0000899243-21-011747","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-011747","line_url":"/filing/0000899243-21-011747#line-2","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821074","owner_name":"Jacobs Bruce N.","owner_display_name":"Jacobs Bruce N.","owner_url":"/insider/0001821074","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1805.0,"shares_display":"1,805","price_per_share":60.0731,"price_display":"60.07","price_state":"stated","total_value":108431.9455,"total_display":"108,431.95","total_whole":"108,432","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-11","filed_date":"2021-03-15","scope":"insider"},{"id":4920804,"accession":"0000899243-21-010463","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-21-010463","line_url":"/filing/0000899243-21-010463","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821074","owner_name":"Jacobs Bruce N.","owner_display_name":"Jacobs Bruce N.","owner_url":"/insider/0001821074","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":50.64700913,"price_display":"50.65","price_state":"stated","total_value":506470.0913,"total_display":"506,470.09","total_whole":"506,470","shares_owned_after":2301.0,"shares_owned_after_display":"2,301","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-08","filed_date":"2021-03-08","scope":"insider","n_lines":3},{"id":4084032,"accession":"0000899243-21-010156","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-21-010156","line_url":"/filing/0000899243-21-010156","is_derivative":false,"issuer_cik":"0001815442","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001815442","owner_cik":"0001821074","owner_name":"Jacobs Bruce N.","owner_display_name":"Jacobs Bruce N.","owner_url":"/insider/0001821074","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":44.78168934,"price_display":"44.78","price_state":"stated","total_value":895633.7868,"total_display":"895,633.79","total_whole":"895,634","shares_owned_after":1100.0,"shares_owned_after_display":"1,100","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-03","filed_date":"2021-03-05","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":41,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":41,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":41},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001815442","name":"Kymera Therapeutics, Inc.","url":"/issuer/0001815442","role":"Officer (Chief Financial Officer)","n_filings":13,"first_seen":"2021-03-05","last_seen":"2026-07-02"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001821074","retrieved_at":"2026-08-24T19:51:24+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}